Table 2 Hepatotoxicity adverse event signals of HER2-targeted drugs.

From: Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis

Drugs

a

b

c

d

ROR (95%Cl)

P value

Trastuzumab

1501

69,304

327,360

40,120,714

2.65 (2.52–2.79)

reference

T-DM1

547

11,158

328,314

40,178,860

6 (5.51–6.54)

0.000

T-DXd

325

15,830

328,536

40,174,188

2.51 (2.25–2.8)

0.202

Pertuzumab

301

21,273

328,560

40,168,745

1.73 (1.54–1.94)

0.000

TKIs

312

16,138

328,549

40,173,880

2.36 (2.11–2.64)

0.037

  1. Note: T-DM1, Trastuzumab emtansine; T-DXd, Trastuzumab deruxtecan; TKIs, Lapatinib, neratinib, and tucatinib; ROR, Reporting Odds Ratios; CI, Confidence Intervals.
Back to article page